Influence of antithyroid drugs on the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre

European Journal of Nuclear Medicine

Volumn 29, Issue 1, 2002, Pages 160-161

  Sabri, O ^a,b   Zimny, M ^a,b   Buell, U ^a,b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; CARBIMAZOLE; RADIOACTIVE IODINE;

DRUG HALF LIFE; DRUG UPTAKE; DRUG WITHDRAWAL; ENERGY; FOLLOW UP; GRAVES DISEASE; HUMAN; LETTER; RADIATION ABSORPTION; RADIATION DOSE; RADIATION EXPOSURE; THYROID WEIGHT; TOXIC GOITER; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0036170388     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-001-0673-5     Document Type: Letter

References (6)

1. 1. C Körber P Schneider N Körber-Hafner H Hänscheid C Reiners 2001 Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves’ disease and toxic nodular goitre? Eur J Nucl Med 28 1360 1364 11585295 10.1007/s002590100565 Körber C, Schneider P, Körber-Hafner N, Hänscheid H, Reiners C. Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves’ disease and toxic nodular goitre? Eur J Nucl Med 2001; 28:1360–1364.
2. 2. O Sabri M Zimny G Schulz M Schreckenberger P Reinartz K Willmes U Buell 1999 Success rate of radioiodine therapy in Graves’ disease: the influence of thyrostatic medication J Clin Endocrinol Metab 84 1229 1233 1:CAS:528:DyaK1MXisVyrsbg%3D 10199759 Sabri O, Zimny M, Schulz G, Schreckenberger M, Reinartz P, Willmes K, Buell U. Success rate of radioiodine therapy in Graves’ disease: the influence of thyrostatic medication. J Clin Endocrinol Metab 1999; 84:1229–1233.
3. 3. O Sabri M Zimny M Schreckenberger P Reinartz E Ostwald U Buell 1999 Radioiodine therapy in Graves’ disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy Thyroid 9 1181 1188 1:STN:280:DC%2BD3c7htVGktA%3D%3D 10646656 10.1089/thy.1999.9.1181 Sabri O, Zimny M, Schreckenberger M, Reinartz P, Ostwald E, Buell U. Radioiodine therapy in Graves’ disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy. Thyroid 1999; 9:1181–1188.
4. 4. O Sabri M Zimny M Schreckenberger P Reinartz B Nowak E Ostwald W Schäfer S Block K Setani U Büll 2001 Characterization of radioiodine therapy failures in Graves’ disease Nuklearmedizin 40 1 6 1:STN:280:DC%2BD3M3ptFGitA%3D%3D 11373933 Sabri O, Zimny M, Schreckenberger M, Reinartz P, Nowak B, Ostwald E, Schäfer W, Block S, Setani K, Büll U. Characterization of radioiodine therapy failures in Graves’ disease. Nuklearmedizin 2001; 40:1–6.
5. 5. D Moka H Schicha C Körber P Schneider C Reiners 2000 Reduzieren Thyreostatika die Erfolgsrate in der Radioiodtherapie? Nuklearmedizin 39 N25 N26 Moka D, Schicha H, Körber C, Schneider P, Reiners C. Reduzieren Thyreostatika die Erfolgsrate in der Radioiodtherapie? Nuklearmedizin 2000; 39:N25–N26.
6. 6. V Urbannek E Voth D Moka H Schicha 2001 Raioiodine therapy of Graves’ disease-a dosimetric comparison of different strategies concerning antithyroid drugs Nuklearmedizin 40 111 115 1:STN:280:DC%2BD3MrgvVeiug%3D%3D 11556200 Urbannek V, Voth E, Moka D, Schicha H. Raioiodine therapy of Graves’ disease-a dosimetric comparison of different strategies concerning antithyroid drugs. Nuklearmedizin 2001; 40:111–115.